Li Yuan-Yuan, Guo Rong-Juan, Xie Yan-Ming, Lin Ya-Ming, Cai Ye-Feng, Zhao Jian-Jun, Guo Tao, Zhang Ling
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
Dongfang Hospital, Beijing University of Chinese Medicine Beijing 100078, China.
Zhongguo Zhong Yao Za Zhi. 2020 May;45(10):2296-2299. doi: 10.19540/j.cnki.cjcmm.20200217.501.
With the advancement of the aging process, cerebrovascular disease has become China's first cause of death. Injection of Breviscapine is a type of traditional Chinese medicine injections published in the Chinese Pharmacopoeia of 2015 Edition and the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalogue, and used to treat ischemic cerebrovascular disease in clinic. In order to further improve clinicians' understanding of the drug and guidance of its rational clinical use, we gave full consideration of clinical research evidences and expert experience, followed the procedures developed based on expert consensus of Chinese Academy of Traditional Chinese Medicine, and then offered recommendations for clinical problems summarized by clinical first-line investigations and evidence-based clinical problems according to internationally accepted evidence grading and recommendation standards, i.e. Grade. As for clinical problems without evidence, we reached through nominal group method, and formed consensus recommendations. Safety issues of Injection of Breviscapine, such as indication, syndrome, dosage, course of treatment, precautions, suggestions and contraindications, were defined to improve clinical efficacy, promote rational drug use and reduce drug risks. This consensus needs to be revised in the future based on emerging clinical issues and evidence-based updates in practical applications.
随着老龄化进程的推进，脑血管疾病已成为我国首要死因。注射用灯盏花素是列入《中国药典》2015年版及国家基本医疗保险、工伤保险和生育保险药品目录的一种中药注射剂，临床用于治疗缺血性脑血管疾病。为进一步提高临床医师对该药品的认识及指导临床合理用药，我们充分考虑临床研究证据和专家经验，遵循中国中医科学院专家共识制定的程序，按照国际公认的证据分级和推荐标准即Grade，针对临床一线调研总结的临床问题及循证临床问题给出推荐意见。对于无证据的临床问题，通过名义组法达成共识并形成推荐意见。明确注射用灯盏花素的适应证、证候、剂量、疗程、注意事项、建议及禁忌等安全性问题，以提高临床疗效，促进合理用药，降低用药风险。本共识未来需根据实际应用中出现的临床问题及循证更新情况进行修订。
